Volume 23, Issue 3 (Pajouhan Scientific Journal, Summer 2025)
Pajouhan Sci J 2025, 23(3): 209-217 |
Back to browse issues page
Ethics code: IR.UMSHA.REC.1401.544
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farhadi A, Shakrarmi A H, Kamkari S, Mohammadi Y. Impact of Sinopharm COVID-19 Vaccination during Pregnancy on Neonatal Outcomes: A Retrospective Cohort Study in Iran. Pajouhan Sci J 2025; 23 (3) :209-217
URL: http://psj.umsha.ac.ir/article-1-1205-en.html
URL: http://psj.umsha.ac.ir/article-1-1205-en.html
1- School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,s.kamkari@umsha.ac.ir
3- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
2- Department of Obstetrics and Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
3- Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
Abstract: (1073 Views)
Background and Objectives: The COVID-19 pandemic necessitated urgent global vaccination efforts. The Sinopharm COVID-19 vaccine, developed using inactivated virus technology, has been widely used among pregnant women. The present study aimed to assess the effects of Sinopharm vaccination during pregnancy on neonatal outcomes.
Materials and Methods: This retrospective cohort study included 236 pregnant women at Fatemiyeh Hospital in Hamadan, Iran, between 2021 and 2022. The study included 118 women who received the Sinopharm COVID-19 vaccine (vaccinated group) and 118 unvaccinated women (unvaccinated group). Neonatal outcomes, including preterm birth, birth weight, Apgar scores, congenital anomalies, and neonatal mortality, were assessed and compared between the two groups.
Results: Baseline characteristics, such as maternal age, body mass index, and parity, were similar between the groups (P>0.05). Neonatal mortality was slightly higher in the vaccinated group (0.8% vs. 0% in the unvaccinated group). Nonetheless, no statistically significant differences were observed in other outcomes, including birth weight, congenital anomalies, or rates of spontaneous abortion.
Conclusion: The Sinopharm COVID-19 vaccine appears to be safe for pregnant women, with no significant increase in the risk of adverse neonatal outcomes. These findings support the use of the Sinopharm vaccine in pregnant women for protection against COVID-19, though further long-term studies are warranted.
Materials and Methods: This retrospective cohort study included 236 pregnant women at Fatemiyeh Hospital in Hamadan, Iran, between 2021 and 2022. The study included 118 women who received the Sinopharm COVID-19 vaccine (vaccinated group) and 118 unvaccinated women (unvaccinated group). Neonatal outcomes, including preterm birth, birth weight, Apgar scores, congenital anomalies, and neonatal mortality, were assessed and compared between the two groups.
Results: Baseline characteristics, such as maternal age, body mass index, and parity, were similar between the groups (P>0.05). Neonatal mortality was slightly higher in the vaccinated group (0.8% vs. 0% in the unvaccinated group). Nonetheless, no statistically significant differences were observed in other outcomes, including birth weight, congenital anomalies, or rates of spontaneous abortion.
Conclusion: The Sinopharm COVID-19 vaccine appears to be safe for pregnant women, with no significant increase in the risk of adverse neonatal outcomes. These findings support the use of the Sinopharm vaccine in pregnant women for protection against COVID-19, though further long-term studies are warranted.
Type of Study: Research Article |
Subject:
Medicine & Clinical Sciences
Received: 2025/05/20 | Accepted: 2025/06/1 | Published: 2025/12/29
Received: 2025/05/20 | Accepted: 2025/06/1 | Published: 2025/12/29
References
1. Moshkabadi Mohajer H, Salimifar M, Seifi A. The impact of some socio-economic factors on the nutritional behavior of children and adolescents during the outbreak of COVID-19: a case study of Mashhad, Iran. Pajouhan Sci J. 2023;21(2):83-9. [DOI:10.61186/psj.21.2.83]
2. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(44):1641. [DOI:10.15585/mmwr.mm6944e3] [PMID]
3. Almasi S, Mohammadi R, Rashidi K, Fazli A, Azadbakht H, Dehghani M. Impact of the COVID-19 pandemic and related factors on the occurrence of emotional-behavioral problems in children. Pajouhan Sci J. 2023;21(4):224-34. [DOI:10.61186/psj.21.4.224]
4. Lokken EM, Huebner EM, Taylor GG, Hendrickson S, Vanderhoeven J, Kachikis A, et al. Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State. Am J Obstet Gynecol. 2021;225(1):77.e1-.e14. [DOI:10.1016/j.ajog.2020.12.1221] [PMID]
5. Woodworth KR, Olsen EOM, Neelam V, Lewis EL, Galang RR, Oduyebo T, et al. Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy-SET-NET, 16 jurisdictions, March 29-October 14, 2020. MMWR Morb Mortal Wkly Rep . 2020;69(44):1635-1640. [DOI:10.15585/mmwr.mm6944e2] [PMID]
6. Derakhshanpour F, Alipour N, Maghsoudloo Nejad A. Investigating the state of anxiety disorders in children aged 6-12 years after the COVID-19 pandemic, Gorgan city. Pajouhan Sci J. 2024;22(4):267-78. [DOI:10.32592/psj.22.4.267]
7. Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021;225(3):303.e1-.e17. [DOI:10.1016/j.ajog.2021.03.023] [PMID]
8. Falsaperla R, Leone G, Familiari M, Ruggieri M. COVID-19 vaccination in pregnant and lactating women: a systematic review. Expert Rev Vaccines. 2021;20(12):1619-28. [DOI:10.1080/14760584.2021.1986390] [PMID]
9. Zauche LH, Wallace B, Smoots AN, Olson CK, Oduyebo T, Kim SY, et al. Receipt of mRNA COVID-19 vaccines and risk of spontaneous abortion. N Engl J Med. 2021;385(16):1533-5. [DOI:10.1056/NEJMc2113891] [PMID]
10. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA. 2021;325(13):1318-20. [DOI:10.1001/jama.2021.3199] [PMID]
11. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2-preliminary report. N Engl J Med. 2020;383(20):1920-31. [DOI:10.1056/NEJMoa2022483] [PMID]
12. Organization WH. Job aid for COVID-19 vaccine administration: Beijing Institute of Biological Products Co., Ltd. (BIBP) COVID-19 vaccine, by China National Biotec Group (CNBG), Sinopharm (International non-proprietary name: Covilo; BIBP-CorV): World Health Organization. Regional Office for Europe; 2021.
13. Vukčević M, Šerović K, Despot M, Nikolić-Kokić A, Vujović A, Nikolić M, et al. Humoral and cellular immune response after three doses of Sinopharm [Vero Cell]-inactivated COVID-19 vaccine in combination with SARS-CoV-2 infection leads to hybrid immunity. Pharmaceuticals. 2024;17(1):122. [DOI:10.3390/ph17010122] [PMID]
14. Abdulla ZA, Al-Bashir SM, Al-Salih NS, Aldamen AA, Abdulazeez MZ. A Summary of the SARS-CoV-2 vaccines and technologies available or under development. Pathogens. 2021;10(7):788. [DOI:10.3390/pathogens10070788] [PMID]
15. Goldshtein I, Nevo D, Steinberg DM, Rotem RS, Gorfine M, Chodick G, et al. Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women. JAMA. 2021;326(8):728-35. [DOI:10.1001/jama.2021.11035] [PMID]
16. Zare Sakhvidi M, Lotfi MH, Fallahzadeh H, Hosseini S, Kalantari F, Taheri Soodejani M. COVID-19 vaccine in pregnant women and pregnancy outcomes: a historical cohort in center of Iran. Women's Health. 2023;19:17455057231189554. [DOI:10.1177/17455057231189554] [PMID]
17. Askary E, Moradi Alamdarloo S, Keshtvarz Hesam Abadi A. Safety of COVID-19 vaccination in pregnant women and their neonatal outcome: a narrative Review. J Matern Fetal Neonatal Med. 2023;36(1):2183750. [DOI:10.1080/14767058.2023.2183750] [PMID]
18. Shafiee A, Kohandel Gargari O, Teymouri Athar MM, Fathi H, Ghaemi M, Mozhgani S-H. COVID-19 vaccination during pregnancy: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2023;23(1):45. [DOI:10.1186/s12884-023-05374-2] [PMID]
19. Santos J, Miller M, Branda ME, Mehta RA, Theiler RN. Maternal COVID-19 vaccination status and association with neonatal congenital anomalies. Front Pediatr. 2024; 12:1355502. [DOI:10.3389/fped.2024.1355502] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences.
Published by UMSHA Press
Journal Tel: +98 81 38380090
Publisher Tel: +98 81 38382022
Website: https://psj.umsha.ac.ir/
Email: psj@umsha.ac.ir
